lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
270 rows where filing_period = "fourth_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2057445 | RED+BLUE STRATEGIES dfe1d04b-09c5-4256-aa9b-5e9bdced1e35 | Q4 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2017 | fourth_quarter | PHA | Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-02T10:09:20.523000-05:00 | |
| 2057954 | AMERICAN COLLEGE OF CLINICAL PHARMACY e6e984b7-e81c-4a6d-a595-630f36b63ad5 | Q4 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2017 | fourth_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 128375 | 0 | 0 | 2018-01-04T09:46:44.613000-05:00 | |
| 2058245 | AMERICAN PHARMACISTS ASSOCIATION 643b61ab-6146-41a2-ba4a-da13cb0ea3a6 | Q4 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2017 | fourth_quarter | PHA | HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importation Act HR 3727 To amend title XVIII of t… | HOUSE OF REPRESENTATIVES,SENATE | 34000 | 0 | 0 | 2018-01-05T14:21:42.550000-05:00 | |
| 2058767 | AMERICAN CAPITOL GROUP c08eb5f7-acb0-46d7-a5a5-be285380f66c | Q4 | AMERICAN CAPITOL GROUP | 305852 | CARDINAL HEALTH | 2017 | fourth_quarter | PHA | Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2018-01-09T09:31:48.527000-05:00 | |
| 2059350 | PARRY, ROMANI, DECONCINI & SYMMS 57af036b-c922-40a8-94fd-56073f4778e6 | Q4 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 12000 | 0 | 0 | 2018-01-10T11:49:54.897000-05:00 | |
| 2059687 | LUNGREN LOPINA LLC 4eccb1d8-dafd-4c7d-9e50-f07218465364 | Q4 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2017 | fourth_quarter | PHA | Fair treatment for US pharmaceutical ingredients | 40000 | 0 | 0 | 2018-01-10T15:34:09.853000-05:00 | ||
| 2059821 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 77959816-d900-4c89-9142-06065f112062 | Q4 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2017 | fourth_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-10T16:52:50.220000-05:00 | |
| 2059916 | ACG ADVOCACY 0876944e-5682-4d4a-9759-46ac67c10a63 | Q4 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2017 | fourth_quarter | PHA | Competition Policy Issues. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-01-10T19:00:24.260000-05:00 | |
| 2059965 | MR. BRIAN KELLY 48c94aa8-ea55-4dde-88f2-e3069310e3b6 | 4T | MR. BRIAN KELLY | 40024191 | LUNDBECK PHARMACEUTICALS | 2017 | fourth_quarter | PHA | CNS Brain Disorders Alzheimer's | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 1 | 2018-01-11T09:46:36.007000-05:00 | |
| 2060061 | BALLARD PARTNERS 3e537baf-fbed-4669-a051-9067bd95dce0 | Q4 | BALLARD PARTNERS | 401104288 | LABORATORY CORPORATIONS OF AMERICA HOLDINGS | 2017 | fourth_quarter | PHA | The registrant will advise and advocate for the client on general government policies and regulations. | Health & Human Services, Dept of (HHS),White House Office | 60000 | 0 | 0 | 2018-01-11T10:51:51.517000-05:00 | |
| 2060217 | KATE MOSS 129c5579-cfa1-4056-b9a4-3735e5a4c83d | Q4 | KATE MOSS | 25988 | CVS HEALTH | 2017 | fourth_quarter | PHA | Legislation impacting PBMs and drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-01-11T12:03:32.473000-05:00 | |
| 2060281 | FARRAGUT PARTNERS LLP 1c3a123d-a112-4539-a8f3-0c20e304eeff | Q4 | FARRAGUT PARTNERS LLP | 401103938 | AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS | 2017 | fourth_quarter | PHA | Issues pertaining to Prescription Drug Monitoring programs. Public Health. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-11T13:23:52.323000-05:00 | |
| 2060303 | FARRAGUT PARTNERS LLP 9e271216-a5c0-4f40-96ad-c85e4a8b5d35 | Q4 | FARRAGUT PARTNERS LLP | 401103938 | GENENTECH | 2017 | fourth_quarter | PHA | Prescription Drug User Fee Act reathorization. Oversight of 340B drug discount program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-11T13:35:12.157000-05:00 | |
| 2060315 | FARRAGUT PARTNERS LLP 74fdc2d0-cdfd-4cc2-93cf-9d2677a40fc7 | Q4 | FARRAGUT PARTNERS LLP | 401103938 | BLUE CROSS BLUE SHIELD ASSOCIATION | 2017 | fourth_quarter | PHA | Laboratory developed tests 21st Century Cures HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (RMI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan, early stage investigators, and highrisk, highreward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office | 50000 | 0 | 0 | 2018-01-11T13:45:24.867000-05:00 | |
| 2060321 | FARRAGUT PARTNERS LLP 8add122c-e8d0-4199-907e-0f10724abf43 | Q4 | FARRAGUT PARTNERS LLP | 401103938 | COMMUNITY ONCOLOGY ALLIANCE | 2017 | fourth_quarter | PHA | Issues related to pharmacy benefit managers. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-01-11T13:45:30.523000-05:00 | |
| 2060345 | FARRAGUT PARTNERS LLP fb5d627b-f40d-4beb-bd86-be0eabde3c34 | Q4 | FARRAGUT PARTNERS LLP | 401103938 | HERON THERAPEUTICS, INC. | 2017 | fourth_quarter | PHA | Issues related to opioids and FDA issues. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-01-11T13:50:45.587000-05:00 | |
| 2060561 | WAXMAN STRATEGIES 7b5f62df-c48e-404f-875d-4251774889cc | Q4 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2017 | fourth_quarter | PHA | Issues affecting the 340B drug pricing program | HOUSE OF REPRESENTATIVES,SENATE | 18750 | 0 | 0 | 2018-01-11T15:41:03.830000-05:00 | |
| 2060804 | NCHC ACTION FUND cb211d5e-2f50-420f-bfe4-60dadeea34cb | Q4 | NCHC ACTION FUND | 401104187 | NCHC ACTION FUND | 2017 | fourth_quarter | PHA | Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-01-11T20:05:33.167000-05:00 | |
| 2060843 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER a3f58e52-aa52-4d94-8b75-ad32dd64b340 | Q4 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2017 | fourth_quarter | PHA | 340B drug pricing, PREA | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 61052 | 0 | 0 | 2018-01-12T09:04:53.273000-05:00 | |
| 2061009 | AMERICAN COLLEGE OF CLINICAL PHARMACY 10fb36d7-589d-4a1b-b142-b9a98fc34f71 | 4A | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2017 | fourth_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 128375 | 0 | 0 | 2018-01-12T10:02:24.520000-05:00 | |
| 2061223 | MCDERMOTT+ LLC 63f3cebd-3da5-4d78-b7b7-5fb5c148ccfa | Q4 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2017 | fourth_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-01-12T13:27:46.607000-05:00 | |
| 2061533 | ACADEMY OF MANAGED CARE PHARMACY dfc252b9-29eb-480b-8366-8d7631331dc2 | Q4 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2017 | fourth_quarter | PHA | Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act. | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 82000 | 0 | 0 | 2018-01-12T17:45:30.883000-05:00 | |
| 2061537 | INDEPENDENT PHARMACY COOPERATIVE 8e8a44be-4ab5-42cc-a448-13e00e2df559 | Q4 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2017 | fourth_quarter | PHA | Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Support H.R. 2871 the "Preserving Patient Access to Compounded Medications Act of 2017 | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-12T17:50:33.730000-05:00 | |
| 2061583 | THE D MAJOR GROUP 8530e0df-863d-43aa-8875-2cd625253132 | Q4 | THE D MAJOR GROUP | 401103162 | ALLERGAN INC (FORMERLY ACTAVIS INC ) | 2017 | fourth_quarter | PHA | Monitor issues concerning bioequivalence standards for pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 48000 | 0 | 0 | 2018-01-12T21:30:07.730000-05:00 | |
| 2061602 | THE D MAJOR GROUP c4078e3d-af4f-49a0-8ed2-87bdaf9ded43 | 4T | THE D MAJOR GROUP | 401103162 | CVS CAREMARK | 2017 | fourth_quarter | PHA | Advocate for the protection of PBM business methods and corresponding health savings. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2018-01-12T23:12:24.893000-05:00 | |
| 2061611 | RED+BLUE STRATEGIES 4e55940e-4b46-4dd9-904a-ff6a38349c96 | Q4 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2017 | fourth_quarter | PHA | CMS regulations regarding the Part D program and the role of prescription drug plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-13T10:09:39.513000-05:00 | |
| 2061675 | AMERICAN AMBULANCE ASSOCIATION 88635bdf-9101-4c7b-8189-4367b085be76 | Q4 | AMERICAN AMBULANCE ASSOCIATION | 56018 | AMERICAN AMBULANCE ASSOCIATION | 2017 | fourth_quarter | PHA | Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304, S. 916). | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2018-01-13T13:35:11.637000-05:00 | |
| 2061707 | CHATMAN, LLC 4155b9cd-1809-467b-87be-0edeea7b8262 | Q4 | CHATMAN, LLC | 400678024 | LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER | 2017 | fourth_quarter | PHA | Support continuation of Pharmacy 340B program in HRSA. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-01-13T19:12:51.403000-05:00 | |
| 2061771 | RED+BLUE STRATEGIES ee285ca0-8c9c-491a-a067-99001e19ac42 | Q4 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2017 | fourth_quarter | PHA | CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs) S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Issues related to lowering the price of prescription medications in the United States. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-14T18:21:08.607000-05:00 | |
| 2061774 | RED+BLUE STRATEGIES 00ad7851-d810-40d9-9f13-7e7022028938 | Q4 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2017 | fourth_quarter | PHA | CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-14T18:30:10.057000-05:00 | |
| 2061811 | RED+BLUE STRATEGIES ea6c79b3-76de-413f-b05d-e3a2515155f2 | Q4 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2017 | fourth_quarter | PHA | Issues related to curbing the abuse of opioids in the United States. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-15T10:26:06.407000-05:00 | |
| 2061866 | ISEMAN & ASSOCIATES LLC b5bfd22f-6870-4ddb-8c04-a499408bf553 | Q4 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2017 | fourth_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-01-15T10:52:29.570000-05:00 | |
| 2062510 | ELI LILLY AND COMPANY 10d2768f-3305-4929-8b09-eebcf9edd7dc | Q4 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2017 | fourth_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1560000 | 0 | 0 | 2018-01-16T09:09:28.307000-05:00 | |
| 2062952 | MCDERMOTT WILL & SCHULTE LLP d106c9d3-1c50-40bd-b053-2bb083b9fee3 | Q4 | MCDERMOTT WILL & SCHULTE LLP | 24338 | MAXOR NATIONAL PHARMACY SERVICES, LLC | 2017 | fourth_quarter | PHA | Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. (Jeff Miller -- Executive Branch lobbying only, until 1/3/2018.) | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2018-01-16T12:13:10.880000-05:00 | |
| 2063736 | MERCY HEALTH SYSTEM dd461989-dbd1-40d0-a6fa-4291992d4258 | Q4 | MERCY HEALTH SYSTEM | 40043344 | MERCY HEALTH SYSTEM | 2017 | fourth_quarter | PHA | Palliative Care 340 B Drug program Health Care Reform | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-01-16T16:35:27.543000-05:00 | ||
| 2063752 | ELI LILLY AND COMPANY dff15bd4-c873-40b8-a8d8-fc98b109cac6 | 4A | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2017 | fourth_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 2170000 | 0 | 0 | 2018-01-16T16:43:35.120000-05:00 | |
| 2064865 | ROCK & ASSOCIATES 3da5c862-1d91-4972-aa93-dcd17408332e | Q4 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:23:12.120000-05:00 | |
| 2064869 | ROCK & ASSOCIATES 8adc2bcd-88dc-4069-8e5a-afce679a1a37 | Q4 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:24:15.447000-05:00 | |
| 2064873 | ROCK & ASSOCIATES 2716a887-7c1c-40a3-a24b-8ac5ea06e59b | Q4 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:25:16.590000-05:00 | |
| 2064880 | ROCK & ASSOCIATES 70fedf9c-ba4b-4751-814c-71ca767dd32f | Q4 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:26:18.980000-05:00 | |
| 2064887 | ROCK & ASSOCIATES c9c6cbf3-3fa4-4cf3-aea9-349077b59ceb | Q4 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:27:23.417000-05:00 | |
| 2064888 | ROCK & ASSOCIATES ee843bd2-45d7-431a-8f16-8ef422863d5c | Q4 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:28:24.527000-05:00 | |
| 2064899 | ROCK & ASSOCIATES f694385d-0ee2-425d-8e9c-7f142f6b6f42 | 4A | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:30:29.370000-05:00 | |
| 2064901 | ROCK & ASSOCIATES f66bcc4c-7cbb-4e20-ae9a-55e84eb42fc2 | Q4 | ROCK & ASSOCIATES | 33545 | PRECISION PHARMACY | 2017 | fourth_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2018-01-17T12:31:30.837000-05:00 | |
| 2065022 | SQUIRE PATTON BOGGS 6a7f6940-3771-48d0-91fb-d6bc986717fe | Q4 | SQUIRE PATTON BOGGS | 30906 | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2017 | fourth_quarter | PHA | Monitoring legislation that could impact pharmaceutical industry. | Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-01-17T13:21:44.253000-05:00 | |
| 2065086 | AMERICAN CONSERVATIVE UNION 74c5c464-e0e9-491f-83e3-86ef49f5941f | Q4 | AMERICAN CONSERVATIVE UNION | 62712 | AMERICAN CONSERVATIVE UNION | 2017 | fourth_quarter | PHA | S.974 - CREATES Act of 2017 H.R.2212 - CREATES Act of 2017 | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),U.S. Trade Representative (USTR),White House Office | 10000 | 0 | 0 | 2018-01-17T13:29:16.920000-05:00 | |
| 2065245 | WINNING STRATEGIES WASHINGTON e6fac8a1-5803-4262-b4c6-57db3aceb96b | Q4 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2017 | fourth_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 30000 | 0 | 0 | 2018-01-17T14:00:34.160000-05:00 | |
| 2065452 | HOLLAND & KNIGHT LLP 4432a598-062e-4751-998e-e991e4326eab | Q4 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2017 | fourth_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2018-01-17T14:40:04.870000-05:00 | |
| 2065508 | HOLLAND & KNIGHT LLP cb915216-d37d-4dfb-a95d-f7cacda05d96 | Q4 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2017 | fourth_quarter | PHA | Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-17T14:54:46.460000-05:00 | |
| 2065594 | MERCURY PUBLIC AFFAIRS, LLC 8dfdd9bc-ec03-4215-b3ed-a424ec3ff1e0 | Q4 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | MORRIS AND DICKSON | 2017 | fourth_quarter | PHA | IT Help RE Improper Prescriptions | Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) | 20000 | 0 | 0 | 2018-01-17T15:11:47.080000-05:00 | |
| 2066035 | QUADRIPOINT STRATEGIES LLC edb1cba1-1171-40dd-ac5b-e1ad1f276e2e | Q4 | QUADRIPOINT STRATEGIES LLC | 40002020 | KALEO, INC | 2017 | fourth_quarter | PHA | opioid epidemic, naloxone availability | Health & Human Services, Dept of (HHS),Office of the Vice President of the United States,White House Office | 20000 | 0 | 0 | 2018-01-17T17:00:57.440000-05:00 | |
| 2066120 | SORINI, SAMET & ASSOCIATES, LLC a05461d7-94c0-46eb-aa8a-91fa53a3b7b5 | Q4 | SORINI, SAMET & ASSOCIATES, LLC | 317754 | PETSMART, INC. | 2017 | fourth_quarter | PHA | Veterinary prescriptions | HOUSE OF REPRESENTATIVES,Intl Trade Administration (ITA),SENATE,U.S. International Trade Commission (ITC) | 20000 | 0 | 0 | 2018-01-17T17:34:47.760000-05:00 | |
| 2066160 | KOUNTOUPES DENHAM CARR & REID, LLC 278f76c2-da8b-443d-89ec-fecff3e59833 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | GLENMARK PHARMACEUTICALS, INC., USA | 2017 | fourth_quarter | PHA | General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-17T17:51:11.193000-05:00 | |
| 2066324 | BROYDRICK & ASSOCIATES 1543845c-0f4c-444e-9ec0-cae1c591bb04 | Q4 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2017 | fourth_quarter | PHA | Funding for a new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2018-01-17T20:59:19.830000-05:00 | |
| 2066622 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 34988295-d36f-4cc9-b8f5-77577b1279b9 | Q4 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2017 | fourth_quarter | PHA | Pricing, shortages, and safety issues | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 176300 | 0 | 0 | 2018-01-18T08:42:46.307000-05:00 | |
| 2066777 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d6c0b808-e1b3-4f79-a4fa-c9554adc6e06 | Q4 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2017 | fourth_quarter | PHA | Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 353232 | 0 | 0 | 2018-01-18T09:46:08.443000-05:00 | |
| 2066855 | ELI LILLY AND COMPANY c9ca1bd6-6a7c-478d-bcb5-6eb8cd72c5f5 | 4A | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2017 | fourth_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 2170000 | 0 | 0 | 2018-01-18T09:59:45.270000-05:00 | |
| 2067100 | KOUNTOUPES DENHAM CARR & REID, LLC e462f6e4-0b8e-496a-967f-a7804441c3a4 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2017 | fourth_quarter | PHA | Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2018-01-18T10:53:55.693000-05:00 | |
| 2067352 | AKIN GUMP STRAUSS HAUER & FELD e6b5e1c6-b40d-4071-a889-ac994785335f | Q4 | AKIN GUMP STRAUSS HAUER & FELD | 682 | PHARMEDIUM SERVICES, LLC | 2017 | fourth_quarter | PHA | Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2018-01-18T11:42:23.037000-05:00 | |
| 2067645 | KOUNTOUPES DENHAM CARR & REID, LLC c2c5299a-c39b-4e40-a4d8-56686061ce8a | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | fourth_quarter | PHA | General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-18T12:54:50.190000-05:00 | |
| 2067755 | MASSACHUSETTS MEDICAL SOCIETY fc4c8674-ba4e-487f-a299-c4742f663f91 | Q4 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2017 | fourth_quarter | PHA | S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-18T13:28:07.167000-05:00 | |
| 2067770 | OREGON HEALTH & SCIENCE UNIVERSITY 0d03fdf2-7eae-4e56-99c7-952aa5b720d9 | Q4 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2017 | fourth_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2018-01-18T13:30:17.057000-05:00 | |
| 2068006 | ICE MILLER LLP 22a28975-c005-423d-a413-936df38fd766 | Q4 | ICE MILLER LLP | 67854 | ELI LILLLY AND COMPANY | 2017 | fourth_quarter | PHA | Issues related to pharmaceutical research and manufacturing | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2018-01-18T14:10:53.013000-05:00 | ||
| 2068046 | 340B HEALTH 50326065-8138-44b6-b508-12a50b476590 | Q4 | 340B HEALTH | 316434 | 340B HEALTH | 2017 | fourth_quarter | PHA | The 340B Drug Pricing Program, FY18 LHHS Appropriations, final 2018 Outpatient Prospective Payment System Rule, final rule and new proposed rule concerning 340B ceiling price calculations and manufacturer civil monetary penalties | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 255010 | 0 | 0 | 2018-01-18T14:19:15.950000-05:00 | |
| 2068076 | MERCURY PUBLIC AFFAIRS, LLC 11bcbce8-e6e1-432f-a67e-8d913ee3ca23 | Q4 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2017 | fourth_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2018-01-18T14:23:32.230000-05:00 | |
| 2068136 | NELSON MULLINS RILEY & SCARBOROUGH 097f443f-31ce-403d-95d7-ef9aba6f7b97 | Q4 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2017 | fourth_quarter | PHA | Issues related to the 340B Drug Pricing Program and biomedical research | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-01-18T14:32:08.337000-05:00 | |
| 2068631 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 26140bc1-2d47-4c5e-8c43-78b6f99aa9a2 | Q4 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2017 | fourth_quarter | PHA | Representation on health-related issues including reimbursement, research, public-health & clinical care | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2018-01-18T15:46:16.693000-05:00 | |
| 2068781 | CARD & ASSOCIATES, LLC 7743b331-7f3c-416b-9133-144db1a90f91 | Q4 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2017 | fourth_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 CMS-4182-P Technical Changes Defining Mail Order Pharmacy and Retail Pharmacy Comments | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-18T16:18:56.433000-05:00 | |
| 2068980 | PUBLIC CITIZEN 6b9a6189-6896-4c57-8389-fb9e41dcdb61 | Q4 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2017 | fourth_quarter | PHA | S 771/HR1776-Improving access to affordable prescription drugs act, S 2011/HR 4138-Medicare Price Negotiation Act of 2017, S 252-Medicare Drug Savings Act of 2017, S 1369/HR 2974-Stop Price Gouging Act, S 124-Preserve access to affordable generics act, HR 4117-Competitive DRUGS Act of 2017, S 974/HR 2212-CREATES act of 2017, HR 2051-FAST generics Act of 2017, S 495-Medicare Innovation Prize Fund Act, S 1131.HR 2439-FAIR Drug Pricing act, HR 4116-Transparent Drug Pricing Act of 2017, S 1509-Orphan Products extension accelerating cures and treatments, HR 1223-OPEN act, S 1390-Stronger Patriots Act of 2017, S 1827-KIDS Act of 2017, HR 1628-American Health care act of 2017, HR 3921-Healthy KIDS Act, HR 4116-Transparent drug pricing act of 2017, Bipartisan Health Care Stabilization Act of 2017, biologic market exclusivity, inter partes review, direct to consumer advertising, Over-the-counter Monograph Safety Innovation and Reform act of 2017, Azar HHS nomination, | Agriculture, Dept of (USDA),Education, Dept of,Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Office of Government Ethics (OGE),Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR),White House Office | 70000 | 0 | 0 | 2018-01-18T16:48:57.820000-05:00 | |
| 2069031 | SIMS STRATEGIES, LLC 66ac3f90-1018-4021-b6ba-1a5dadf63a3e | Q4 | SIMS STRATEGIES, LLC | 401104546 | GLAXOSMITHKLINE, INC. | 2017 | fourth_quarter | PHA | Education and importance of various pharmaceutical industry issues. | SENATE | 40000 | 0 | 0 | 2018-01-18T17:00:32.537000-05:00 | |
| 2069048 | SIMS STRATEGIES, LLC 03565ffd-9d94-4c1b-8c63-09dca91fa05f | Q4 | SIMS STRATEGIES, LLC | 401104546 | AMAG PHARMACEUTICAL | 2017 | fourth_quarter | PHA | Education on products and issues related to women's health. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-18T17:05:43.597000-05:00 | |
| 2069128 | KOUNTOUPES DENHAM CARR & REID, LLC d7edd87d-42bf-4e35-9714-3143347d5fba | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | TEVA PHARMACEUTICALS USA, INC. | 2017 | fourth_quarter | PHA | Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2018-01-18T17:19:39.547000-05:00 | |
| 2069246 | PRIME THERAPEUTICS cac71a4a-b278-481a-89b3-1eee731ea89a | Q4 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2017 | fourth_quarter | PHA | S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-18T17:48:46.303000-05:00 | |
| 2069395 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING a0bcf17e-34f3-4ed5-84c5-e63824fe22e8 | Q4 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017 | fourth_quarter | PHA | Compounding of radiopharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 30000 | 0 | 0 | 2018-01-18T18:51:08.053000-05:00 | |
| 2069456 | NATIONAL NURSES UNITED 1633a474-ad99-4f35-a3d6-f0f2f00143a8 | Q4 | NATIONAL NURSES UNITED | 40021153 | NATIONAL NURSES UNITED | 2017 | fourth_quarter | PHA | Supported legislation to permit Medicare Part D to negotiate pharmaceutical prices | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-01-18T19:22:53.467000-05:00 | |
| 2069514 | ALLERGAN USA, INC. dd87d5e7-a5d5-4154-bbb6-b2235c5793f3 | Q4 | ALLERGAN USA, INC. | 63837 | ALLERGAN USA, INC. | 2017 | fourth_quarter | PHA | Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE | 480000 | 0 | 0 | 2018-01-18T20:10:14.827000-05:00 | |
| 2069529 | CONNECT 4 STRATEGIES, LLC a5edbd2c-455f-4626-9c41-29a311a469d8 | Q4 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2017 | fourth_quarter | PHA | s916 Access to Emergency Medications Act | SENATE | 20000 | 0 | 0 | 2018-01-18T20:26:26.763000-05:00 | |
| 2069566 | NOVO NORDISK INC. 09631fcb-958e-4d90-b197-8c7d8a6e69e0 | Q4 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2017 | fourth_quarter | PHA | Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE | 290000 | 0 | 0 | 2018-01-18T21:09:00.640000-05:00 | |
| 2070227 | NELSON MULLINS RILEY & SCARBOROUGH 852d888b-59ce-4237-9692-b9d4f012e96f | Q4 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2017 | fourth_quarter | PHA | Issues related to 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-01-19T09:29:35.667000-05:00 | |
| 2070298 | AMERICAN VETERINARY MEDICAL ASSOCIATION a0c92150-d8fe-43cb-b832-fc0ad6144287 | Q4 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2017 | fourth_quarter | PHA | H.R. 623 Fairness to Pet Owners Act Animal Drug User Fee Act; Animal Generic Drug User Fee Act | Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 160000 | 0 | 0 | 2018-01-19T09:39:06.867000-05:00 | |
| 2070364 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH cf2625d8-8087-4576-869d-c6ddd21fa8fc | Q4 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2017 | fourth_quarter | PHA | Strengthening the Orphan Drug Tax Credit provision within the final bill, or at the very least ensuring the Senates 27.5 percent credit remains intact | Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Treasury, Dept of | 24400 | 0 | 0 | 2018-01-19T09:47:51.707000-05:00 | |
| 2070421 | AARP e20d3370-3da6-425c-b707-6e7684a9da4e | Q4 | AARP | 1694 | AARP | 2017 | fourth_quarter | PHA | Provided comments to CMS on value-based pricing arrangements for prescription drugs. S. 974/H.R. 2212, CREATES Act - Discussed support of bill. H.R. 2051, FAST Generics Act - Discussed support of bill. S.1131/H.R. 2439, FAIR Drug Pricing Act - Discussed support of bill. S. 124, Preserve Access to Affordable Generics Act - Discussed support of bill. Advocated for biosimilar drugs to be added to the Medicare Part D Coverage Gap Discount Program. Cody Miller PMI Act - Participated in meetings with the sponsoring office to discuss updates to the bill text and re-introduction in the 115th Congress. Submitted a letter outlining the reforms we support to lower prescription drugs costs to the House Energy and Commerce Committee and the Senate HELP Committee when they held hearings on the drug supply chain. Discussed possible ways to improve Medicare Part D. Discussed Rx Price Watch Reports and the impact of high drug costs. Discussed drug pricing reforms AARP supports, including secretarial negotiation, importation, reducing exclusivity for biologics, and ending pay-for-delay deals. H.R. 3354, Omnibus Appropriations Act, 2018, H.R. 1370, H.J.R. 123, Further Continuing Appropriations Act, 2018, H.J. Res. 99 (P.L. 115-30), H.R. 244, Consolidated Appropriations Act 2017 (P.L. 115-31) and (H.R. 3358 & S. 1771) Agriculture-Rural Development & Related Agencies bill for FY 2018 - Lobbied in support of increased funding for FDA drug processing funding and user fees. | Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Highway Traffic Safety Administration (NHTSA),Securities & Exchange Commission (SEC),SENATE,Veterans Affairs, Dept of (VA) | 3020000 | 0 | 0 | 2018-01-19T09:53:31.067000-05:00 | |
| 2070467 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION e2f0f82d-3494-4825-88f0-81a0eeebb888 | Q4 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2017 | fourth_quarter | PHA | Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Economic Council (NEC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Treasury, Dept of,White House Office | 480000 | 0 | 0 | 2018-01-19T10:00:58.767000-05:00 | |
| 2070987 | HUSCH BLACKWELL, LLP a2245e17-923d-4d02-b07d-ef5bf13eb4d1 | Q4 | HUSCH BLACKWELL, LLP | 6303 | ARJ INFUSION SERVICES, INC. | 2017 | fourth_quarter | PHA | Issues related to home infusion therapy; S.1738 | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2018-01-19T10:47:21.297000-05:00 | |
| 2071094 | FTI GOVERNMENT AFFAIRS 03b22b7a-f486-4613-9729-15556e3854f5 | Q4 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2017 | fourth_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-19T10:55:42.817000-05:00 | |
| 2071145 | FORGE FEDERAL AFFAIRS LLC 8ceea5fc-0372-43f1-be6b-4066e8425920 | Q4 | FORGE FEDERAL AFFAIRS LLC | 400865535 | LILLY USA LLC | 2017 | fourth_quarter | PHA | Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. | HOUSE OF REPRESENTATIVES | 20000 | 0 | 0 | 2018-01-19T11:00:22.127000-05:00 | |
| 2071442 | BLUECROSS BLUESHIELD OF TENNESSEE 33d51643-eb27-47be-a3c8-f541a55ef119 | Q4 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2017 | fourth_quarter | PHA | General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing; generic drug issues; HR2051; HR22312. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-19T11:21:27.633000-05:00 | |
| 2071451 | ALKERMES, INC. 2cccfc7e-1735-43b4-b33a-45ec0789ef3e | Q4 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2017 | fourth_quarter | PHA | Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA) | 1000000 | 0 | 0 | 2018-01-19T11:21:33.290000-05:00 | |
| 2071956 | COVINGTON & BURLING LLP a0c4f323-0628-4c97-ac33-24f6866b6b51 | Q4 | COVINGTON & BURLING LLP | 11195 | CELGENE CORPORATION | 2017 | fourth_quarter | PHA | Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-19T11:56:12.140000-05:00 | |
| 2072082 | BOCKORNY GROUP, INC. a4111502-f22a-4896-9fbb-f114d09466ed | Q4 | BOCKORNY GROUP, INC. | 289773 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2017 | fourth_quarter | PHA | Issues related to the pharmaceutical industry Issues related to the pharmaceutical drug supply chain | Health & Human Services, Dept of (HHS),Natl Economic Council (NEC),White House Office | 80000 | 0 | 0 | 2018-01-19T12:10:22.543000-05:00 | |
| 2072084 | CAREFIRST BLUECROSS BLUESHIELD 486e94db-4289-4a05-8108-7e3d89ab49e6 | Q4 | CAREFIRST BLUECROSS BLUESHIELD | 401104608 | CAREFIRST BLUECROSS BLUESHIELD | 2017 | fourth_quarter | PHA | Opioid Policy/Substance Use Disorders | HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2018-01-19T12:10:23.857000-05:00 | |
| 2072359 | FOLEY & LARDNER LLP 83d36d57-cc7e-4bc4-9d8f-c74c46cfddf9 | Q4 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2017 | fourth_quarter | PHA | FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2018-01-19T12:39:07.347000-05:00 | |
| 2072364 | KOUNTOUPES DENHAM CARR & REID, LLC 3f8f3a0c-77c2-4edf-9b4c-6c595e0cf135 | Q4 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | 2017 | fourth_quarter | PHA | Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2018-01-19T12:39:09.833000-05:00 | |
| 2072456 | BOCKORNY GROUP, INC. 4b43ffcc-a731-48a2-a0cb-7a9803f25fbe | Q4 | BOCKORNY GROUP, INC. | 289773 | CVS HEALTH INC | 2017 | fourth_quarter | PHA | Issues related to PBM's Issues related to drug supply chain Issues related to drug pricing Issues related to Veterans health Issues related to opioid abuse Issues related to health reform proposals S.637 - Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 H.R.2212 - CREATES Act of 2017 Judiciary issues related to the drug supply chain | Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 120000 | 0 | 0 | 2018-01-19T12:46:06.253000-05:00 | |
| 2072495 | UNIVERSITY OF IOWA 4026d870-2760-4269-a27f-2b3dc72b95e0 | Q4 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2017 | fourth_quarter | PHA | FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program | Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2018-01-19T12:48:23.720000-05:00 | |
| 2072561 | ASTRAZENECA PHARMACEUTICALS LP 91fd9fd6-598b-4634-aa7d-dbfb843ecf0c | Q4 | ASTRAZENECA PHARMACEUTICALS LP | 54073 | ASTRAZENECA PHARMACEUTICALS LP | 2017 | fourth_quarter | PHA | Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 620000 | 0 | 0 | 2018-01-19T12:53:54.907000-05:00 | |
| 2072623 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM ee938e0c-38c8-4c57-a730-65ada8f7eea0 | Q4 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2017 | fourth_quarter | PHA | Graham-Cassidy-Heller HR 1628; S 2312; HR 4710 Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. Telehealth Improvements S 787 Any provision(s) expanding the use/payment/improvements for telehealth services. | HOUSE OF REPRESENTATIVES,SENATE | 29186 | 0 | 0 | 2018-01-19T13:02:28.937000-05:00 | |
| 2072630 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a90f75fe-3c8c-474c-acdc-39e047834c27 | Q4 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | fourth_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 228000 | 0 | 0 | 2018-01-19T13:03:30.217000-05:00 | |
| 2072988 | FOLEY & LARDNER LLP 930ecb7c-e842-4771-ad9d-7c49bf6b0575 | Q4 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2017 | fourth_quarter | PHA | Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2018-01-19T13:34:45.100000-05:00 | |
| 2073009 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 49a9700e-6c9f-4b93-a686-25d829cef9dc | Q4 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES | 18411 | F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 2017 | fourth_quarter | PHA | H.R. 3271 and S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 121189 | 0 | 0 | 2018-01-19T13:36:54.457000-05:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);